Prof. Dr. med. Pietro Vernazza
Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study
Drescher S, Kouyos R, Günthard H, Ledergerber B, Vernazza P, Bernasconi E, Cavassini M, Ambrosioni J, Battegay M, Furrer H, Taffé P, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Yang W, von Wyl V, Swiss HIV Cohort Study. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2013; 58:285-94.
21.10.2013Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study
21.10.2013Clin Infect Dis 2013; 58:285-94
Drescher Sara M, Kouyos Roger D, Günthard Huldrych F, Ledergerber Bruno, Vernazza Pietro, Bernasconi Enos, Cavassini Matthias, Ambrosioni Juan, Battegay Manuel, Furrer Hansjakob, Taffé Patrick, Klimkait Thomas, Aubert Vincent, Shah Cyril, Yerly Sabine, Böni Jürg, Yang Wan-Lin, von Wyl Viktor, Swiss HIV Cohort Study
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients
Beerenwinkel N, Günthard H, Cellerai C, Klimkait T, Böni J, Yerly S, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Battegay M, Furrer H, von Wyl V, Knupfer P, Schuhmacher H, Montazeri H, Swiss HIV Cohort Study. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol 2013; 9:e1003203.
29.08.2013The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients
29.08.2013PLoS Comput Biol 2013; 9:e1003203
Beerenwinkel Niko, Günthard Huldrych F, Cellerai Cristina, Klimkait Thomas, Böni Jürg, Yerly Sabine, Bernasconi Enos, Vernazza Pietro, Cavassini Matthias, Hirschel Bernard, Battegay Manuel, Furrer Hansjakob, von Wyl Viktor, Knupfer Patrick, Schuhmacher Heike, Montazeri Hesam, Swiss HIV Cohort Study
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study
Bertisch B, Clifford G, Stöckle M, Cavassini M, Calmy A, Wandeler G, Kovari H, Pawlita M, ess s, Jundt G, Levi F, Dehler S, Bouchardy C, Schöni-Affolter F, Keiser O, Vernazza P, Lise M, Franceschi S, Swiss HIV Cohort Study Investigators. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol 2013; 178:877-84.
30.07.2013Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study
30.07.2013Am J Epidemiol 2013; 178:877-84
Bertisch Barbara, Clifford Gary, Stöckle Marcel, Cavassini Matthias, Calmy Alexandra, Wandeler Gilles, Kovari Helen, Pawlita Michael, ess silvia, Jundt Gernot, Levi Fabio, Dehler Silvia, Bouchardy Christine, Schöni-Affolter Franziska, Keiser Olivia, Vernazza Pietro, Lise Mauro, Franceschi Silvia, Swiss HIV Cohort Study Investigators
Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PloS one 2013; 8
25.07.2013Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
25.07.2013PloS one 2013; 8
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, the Swiss HIV Cohort Study (SHCS)
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013; 208:1102-12.
11.07.2013Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
11.07.2013J Infect Dis 2013; 208:1102-12
Metzner Karin J, Aubert Vincent, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Weber Rainer, Günthard Huldrych F, Klimkait Thomas, Yerly Sabine, Böni Jürg, Scherrer Alexandra U, Preiswerk Benjamin, Joos Beda, von Wyl Viktor, Leemann Christine, Rieder Philip, Braun Dominique, Grube Christina, Kuster Herbert, Swiss HIV Cohort Study
Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative
Rodger A, Lundgren J, Phillips A, Corbelli G, Van Lunzen J, Estrada V, Collins S, Vernazza P, Bruun T, PARTNER Study Group. Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Antivir Ther (Lond) 2013; 18:285-7.
24.04.2013Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative
24.04.2013Antivir Ther (Lond) 2013; 18:285-7
Rodger Alison J, Lundgren Jens D, Phillips Andrew N, Corbelli Giulio M, Van Lunzen Jan, Estrada Vicente, Collins Simon, Vernazza Pietro, Bruun Tina, PARTNER Study Group
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)
Nüesch R, Bucher H, Battegay M, Calmy A, Thurnheer M, Vernazza P, Cavassini M, Weber R, Bernasconi E, Elzi L, Wang Q, Swiss HIV Cohort Study. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013; 62:396-404.
01.04.2013Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)
01.04.2013J Acquir Immune Defic Syndr 2013; 62:396-404
Nüesch Reto, Bucher Heiner C, Battegay Manuel, Calmy Alexandra, Thurnheer Maria C, Vernazza Pietro, Cavassini Matthias, Weber Rainer, Bernasconi Enos, Elzi Luigia, Wang Qing, Swiss HIV Cohort Study
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial
Vernazza P, Craig C, Mori J, Goodrich J, Valdez H, Lazzarin A, Kaplan R, Cooper D, Pulik P, Weil E, Pozniak A, Wang C, Tawadrous M. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr 2013; 62:171-9.
01.02.2013Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial
01.02.2013J Acquir Immune Defic Syndr 2013; 62:171-9
Vernazza Pietro, Craig Charles, Mori Julie, Goodrich James, Valdez Hernan, Lazzarin Adriano, Kaplan Richard, Cooper David A, Pulik Piotr, Weil Elizabeth, Pozniak Anton, Wang Cunshan, Tawadrous Margaret
Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy
Du Pasquier R, Vernazza P, Cavassini M, Günthard H, Cusini A, Gutmann C, Fux C, Yerly S, Kalubi M, Jilek S, Swiss HIV Cohort Study. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 2013; 27:203-10.
14.01.2013Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy
14.01.2013AIDS 2013; 27:203-10
Du Pasquier Renaud A, Vernazza Pietro, Cavassini Matthias, Günthard Huldrych F, Cusini Alexia, Gutmann Christine, Fux Christoph A, Yerly Sabine, Kalubi Malela, Jilek Samantha, Swiss HIV Cohort Study
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62:28-35.
01.01.2013Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
01.01.2013J Acquir Immune Defic Syndr 2013; 62:28-35
Cusini Alexia, Günthard Huldyrich F, Opravil Milos, Gutmann Christine, Zenger Franziska, Klimkait Thomas, Cavassini Matthias, Gaudenz Roman, Hirschel Bernhard, Widmer Nicolas, Rohrbach Janine, Fux Christoph A, Ledergerber Bruno, Decosterd Laurent A, Yerly Sabine, Vernazza Pietro, Swiss HIV Cohort Study
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PloS one 2012; 7:e50307.
26.11.2012Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
26.11.2012PloS one 2012; 7:e50307
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, Swiss HIV Cohort Study (SHCS)
Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial
Vernazza P, Craig C, Mori J, Goodrich J, Valdez H, Lazzarin A, Kaplan R, Cooper D, Pulik P, Weil E, Pozniak A, Wang C, Tawadrous M. Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial. J Acquir Immune Defic Syndr 2012
31.10.2012Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial
31.10.2012J Acquir Immune Defic Syndr 2012
Vernazza Pietro, Craig Charles, Mori Julie, Goodrich James, Valdez Hernan, Lazzarin Adriano, Kaplan Richard, Cooper David A, Pulik Piotr, Weil Elizabeth, Pozniak Anton, Wang Cunshan, Tawadrous Margaret
[HIV test and prevention]
Bickel A, Vernazza P. [HIV test and prevention]. Internist (Berl) 2012; 53:1179-86.
01.10.2012[HIV test and prevention]
01.10.2012Internist (Berl) 2012; 53:1179-86
Bickel A, Vernazza Pietro
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
Weber R, the Swiss HIV Cohort Study (SHCS), Schultze D, Schöni-Affolter F, Schüpbach J, Speck R, Taffé P, Tarr P, Telenti A, Trkola A, Vernazza P, Ledergerber B, Kowalska J, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Yerly S. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2012
24.09.2012Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
24.09.2012HIV Med 2012
Weber R, the Swiss HIV Cohort Study (SHCS), Schultze D, Schöni-Affolter F, Schüpbach J, Speck R, Taffé P, Tarr P, Telenti A, Trkola A, Vernazza Pietro, Ledergerber B, Kowalska J, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Yerly S
Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study
van Sighem A, Low N, Fraser C, Bezemer D, Jeannin A, Derendinger S, de Wolf F, Gebhardt M, Vernazza P, Bucher H, Glass T, Vidondo B, Swiss HIV Cohort Study. Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study. PloS one 2012; 7:e44819.
14.09.2012Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study
14.09.2012PloS one 2012; 7:e44819
van Sighem Ard, Low Nicola, Fraser Christophe, Bezemer Daniela, Jeannin Andre, Derendinger Steven, de Wolf Frank, Gebhardt Martin, Vernazza Pietro, Bucher Heiner C, Glass Tracy R, Vidondo Beatriz, Swiss HIV Cohort Study
The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study
Wang Q, Fux C, Bucher H, Stoeckle M, Furrer H, Weber R, Hirschel B, Vernazza P, Cavassini M, Bernasconi E, Young J, Swiss HIV Cohort Study. The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study. Antivir Ther (Lond) 2012; 18:337-44.
12.09.2012The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study
12.09.2012Antivir Ther (Lond) 2012; 18:337-44
Wang Qing, Fux Christoph, Bucher Heiner C, Stoeckle Marcel, Furrer Hansjakob, Weber Rainer, Hirschel Bernard, Vernazza Pietro, Cavassini Matthias, Bernasconi Enos, Young Jim, Swiss HIV Cohort Study
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes
Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Erb S, for the Swiss HIV Cohort Study. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. Arch Intern Med 2012:1-9.
13.08.2012Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes
13.08.2012Arch Intern Med 2012:1-9
Elzi Luigia, Battegay Manuel, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Hirschel Bernard, Cavassini Matthias, Ledergerber Bruno, Furrer Hansjakob, Erb Stefan, for the Swiss HIV Cohort Study
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellerai C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS one 2012; 7:e37983.
18.06.2012Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
18.06.2012PloS one 2012; 7:e37983
Scherrer Alexandra U, Günthard Huldrych F, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Cellerai Cristina, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study
Bucher H, Battegay M, Furrer H, Weber R, Hirschel B, Vernazza P, Cavassini M, Wang Q, Magenta L, Glass T, Richter W, Bernasconi E. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 60:135-42.
01.06.2012Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study
01.06.2012J Acquir Immune Defic Syndr 2012; 60:135-42
Bucher Heiner C, Battegay Manuel, Furrer Hansjakob, Weber Rainer, Hirschel Bernard, Vernazza Pietro, Cavassini Matthias, Wang Qing, Magenta Lorenzo, Glass Tracy R, Richter Werner, Bernasconi Enos
Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods
Rodger A, Corbelli G, Van Lunzen J, Estrada V, Collins S, Vernazza P, Weait M, Bruun T, Phillips A, Lundgren J. Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. BMC Public Health 2012; 12:296.
20.04.2012Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods
20.04.2012BMC Public Health 2012; 12:296
Rodger Alison, Corbelli Giulio Maria, Van Lunzen Jan, Estrada Vicente, Collins Simon, Vernazza Pietro, Weait Matthew, Bruun Tina, Phillips Andrew, Lundgren Jens